3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
18
Carcinoma, Hepatocellular
8
Liver Neoplasms
7
Colorectal Neoplasms
3
Unresectable Pancreatic Cancer
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Locally Advanced Pancreatic Cancer
2
Cholangiocarcinoma
2
Solid Tumor Including Thyroid, Bone, Liver, Pancreas
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma Resectable
1
Pancreatic Adenocarcinoma Locally Advanced
1
Liver Metastasis Colon Cancer
1
Liver Diseases
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colorectal Liver Metastases
1
Bile Duct Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Gemcitabine
61
Cisplatin
39
Oxaliplatin
31
Capecitabine
29
Fluorouracil
22
Leucovorin
20
Irinotecan
12
pembrolizumab
11
130-nm albumin-bound paclitaxel
10
durvalumab
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Taxes
6
Platinum
6
Magnetic Resonance Spectroscopy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Docetaxel
5
Carboplatin
5
Immunohistochemistry
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Watchful Waiting
3
Tegafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Electroporation
×
Gastrointestinal
×
Clear all
NCT02430662
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
30 enrolled